News
So far, benefits associated with consistent GLP-1 use in curbing medical spending lack sufficient data-backed evidence. It’s ...
This is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...
The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...
A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...
Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction of the cost of brand-name competitors such as Wegovy and Ozempic.
Shares of WW International Inc. were climbing in Tuesday trading after the company known as WeightWatchers emerged from bankruptcy and announced a new program to support women as they go through ...
Kate Farms has launched high-protein plant-based shakes to tackle "critical nutrition gaps" from GLP-1 use, its first product ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results